Pathological and clinical correlates of FOXP3+ cells in renal allografts duringacute rejection

Détails

ID Serval
serval:BIB_7EB191554F4B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Pathological and clinical correlates of FOXP3+ cells in renal allografts duringacute rejection
Périodique
American journal of transplantation
Auteur⸱e⸱s
Veronese F., Rotman S., Smith R. N., Pelle T. D., Farrell M. L., Kawai T., Benedict Cosimi A., Colvin R. B.
ISSN
1600-6135
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
7
Numéro
4
Pages
914-922
Langue
anglais
Résumé
The localization and significance of regulatory T cells (Treg) in allograft rejection is of considerable clinical and immunological interest. We analyzed 80 human renal transplant biopsies (including seven donor biopsies) with a double immunohistochemical marker for the Treg transcription factor FOXP3, combined with a second marker for CD4 or CD8. Quantitative FOXP3 cell counts were performed and analyzed for clinical and pathologic correlates. FOXP3(+) cells were present in the interstitium in acute cellular rejection (ACR) type I and II, at a greater density than in acute humoral rejection or CNI toxicity (p < 0.01). Most FOXP3(+) cells were CD4(+) (96%); a minority expressed CD8. FOXP3(+)CD4(+) cells were concentrated in the tubules (p < 0.001), suggesting a selective attraction or generation at that site. Considering only patients with ACR, a higher density of FOXP3(+) correlated with HLA class II match (p = 0.03), but paradoxically with worse graft survival. We conclude that infiltration of FOXP3(+) cells occurs in ACR to a greater degree than in humoral rejection, however, within the ACR group, no beneficial effect on outcome was evident. Tregs concentrate in tubules, probably contributing to FOXP3 mRNA in urine; the significance and pathogenesis of 'Treg tubulitis' remains to be determined.
Pubmed
Web of science
Création de la notice
17/12/2008 17:48
Dernière modification de la notice
20/08/2019 15:39
Données d'usage